1,600 units of octaplaslg delivered to blood bank west
Ended Awarded Last action
- Contract number
- HT942726FE009
- Awardee
-
Octapharma USA Inc. UEI FKJKNJVR1HV4
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $1,920,000
Award facts
- Opportunity
-
- HT942525Q0071 Solicitation number
- Contract value 100% obligated
- $1,920,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- Set-aside
- No set-aside
- Competition
- Not Available for Competition Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Paramus, NJ 07652, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency awarded a $1.92M delivery order to Octapharma USA Inc. on January 16, 2026, for the procurement and delivery of 1,600 units of Octaplas LG to Blood Bank West, with an ultimate completion date of May 29, 2026. Octaplas LG is a solvent/detergent-treated liquid plasma product critical for emergency medical treatment, particularly for addressing coagulopathies, hemorrhage control, and clotting factor restoration in military and federal healthcare settings. The contract utilizes a firm fixed-price structure with no small business set-aside designation and represents performance at the contractor's facility in Paramus, New Jersey.
This delivery order is issued under Octapharma USA Inc.'s single-award Indefinite Delivery Contract with the Defense Health Agency, valued at $14.88M with a completion date of September 14, 2030. The master contract, awarded September 15, 2025, encompasses the supply of Octaplas LG powder under Food and Drug Administration Emergency Use Authorization, along with ancillary medical supplies including sterile water for injection, transfusion sets with filters, transfer sets, alcohol swabs, and vented spike adapters. As a foreign-owned pharmaceutical manufacturer specializing in blood plasma products, Octapharma has been registered as a federal contractor since 2005 and provides essential medical supplies supporting military medical readiness and operational medicine capabilities across the military health system.
Quick answers
Who was awarded contract HT942726FE009?
HT942726FE009 was awarded to Octapharma USA Inc. by Defense Health Agency (Department of Defense) on January 16, 2026.
How much is contract HT942726FE009 worth?
The government has obligated $1,920,000 on HT942726FE009.
Is contract HT942726FE009 an order under another contract?
Yes. HT942726FE009 is a delivery order under HT942525DE004, an indefinite delivery contract.
Was contract HT942726FE009 competed?
The extent of competition for HT942726FE009 was not available for competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award